ABBV · News · 20261114N

Licensing / Collaboration Deals

AbbVie Inc. · 2026-11-14 · Importance null · Surprise null

AbbVie’s partner Brise Pharmaceuticals reported progress on two preclinical migraine programs under an exclusive license agreement. The programs met several near-term milestones, while AbbVie retains global development and commercial control and Brise bears the early-stage risk. The report did not specify milestone payments, financial impact, or a timeframe for development or commercialization.

Key facts